JP2014508161A5 - - Google Patents

Download PDF

Info

Publication number
JP2014508161A5
JP2014508161A5 JP2013556833A JP2013556833A JP2014508161A5 JP 2014508161 A5 JP2014508161 A5 JP 2014508161A5 JP 2013556833 A JP2013556833 A JP 2013556833A JP 2013556833 A JP2013556833 A JP 2013556833A JP 2014508161 A5 JP2014508161 A5 JP 2014508161A5
Authority
JP
Japan
Prior art keywords
sequence
independently
present
strand
tlr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013556833A
Other languages
English (en)
Japanese (ja)
Other versions
JP6000287B2 (ja
JP2014508161A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/027169 external-priority patent/WO2012118910A2/en
Publication of JP2014508161A publication Critical patent/JP2014508161A/ja
Publication of JP2014508161A5 publication Critical patent/JP2014508161A5/ja
Application granted granted Critical
Publication of JP6000287B2 publication Critical patent/JP6000287B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013556833A 2011-03-03 2012-03-01 肺疾患および損傷を治療するための組成物および方法 Expired - Fee Related JP6000287B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161448723P 2011-03-03 2011-03-03
US61/448,723 2011-03-03
PCT/US2012/027169 WO2012118910A2 (en) 2011-03-03 2012-03-01 Compositions and methods for treating lung disease and injury

Publications (3)

Publication Number Publication Date
JP2014508161A JP2014508161A (ja) 2014-04-03
JP2014508161A5 true JP2014508161A5 (enExample) 2015-04-16
JP6000287B2 JP6000287B2 (ja) 2016-09-28

Family

ID=45816001

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013556833A Expired - Fee Related JP6000287B2 (ja) 2011-03-03 2012-03-01 肺疾患および損傷を治療するための組成物および方法

Country Status (10)

Country Link
US (2) US9205100B2 (enExample)
EP (1) EP2681314B1 (enExample)
JP (1) JP6000287B2 (enExample)
KR (1) KR101937498B1 (enExample)
CN (1) CN103492572A (enExample)
AU (1) AU2012223365B2 (enExample)
CA (1) CA2828002A1 (enExample)
IL (1) IL228252A (enExample)
SG (1) SG192961A1 (enExample)
WO (1) WO2012118910A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201124160A (en) * 2009-11-26 2011-07-16 Quark Pharmaceuticals Inc SiRNA compounds comprising terminal substitutions
EP2681314B1 (en) 2011-03-03 2017-11-01 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
ES2555160B1 (es) 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos
EP3423568A4 (en) 2016-03-04 2019-11-13 University Of Louisville Research Foundation, Inc. METHOD AND COMPOSITIONS FOR EX-VIVO REPRODUCTION OF VERY SMALL EMBRYONAL STEM CELLS (VSELS)
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
US10975167B2 (en) 2017-04-14 2021-04-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Method to reduce pulmonary arterial hypertension by administering inhibitors of nicotinamide phosphoribotransferase
EP3610018B1 (en) * 2017-04-14 2023-06-07 Arizona Board of Regents on Behalf of the University of Arizona Compositions and methods for treating pulmonary fibrosis
WO2020011869A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting tlr2
CN115176027A (zh) * 2019-12-12 2022-10-11 哈佛大学校长及研究员协会 用于光指导的生物分子条形码化的组合物和方法
US11851707B1 (en) * 2020-03-27 2023-12-26 University Of South Florida N-Myc-Interactor protein as a marker for chronic lung disease and uses thereof
KR102562955B1 (ko) 2021-07-08 2023-08-03 렉스소프트 주식회사 폐 기능 저하 위험 예측용 단일염기다형성 및 이의 용도
CN114796273A (zh) * 2022-07-01 2022-07-29 中国人民解放军总医院第一医学中心 Tlr4激动的外泌体或外泌体制剂在制备防治放射性肺损伤药物中的应用

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JP3012244B2 (ja) 1987-09-21 2000-02-21 ジェン―プローブ インコーポレイテッド ヌクレオチドプローブ用非ヌクレオチド連結試薬
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
ATE515510T1 (de) 1991-12-24 2011-07-15 Isis Pharmaceuticals Inc Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
EP1253199A1 (en) 1993-09-02 2002-10-30 Ribozyme Pharmaceuticals, Inc. Abasic moieties containing enzymatic nucleic acids
CA2170869C (en) 1993-09-03 1999-09-14 Phillip Dan Cook Amine-derivatized nucleosides and oligonucleosides
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
ATE174600T1 (de) 1993-10-27 1999-01-15 Ribozyme Pharm Inc 2'-amido-und 2'-peptido-modifizierte oligonukleotide
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
CA2207593A1 (en) 1994-12-13 1996-06-20 John Gustofson Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
US6235310B1 (en) 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
EP1015469B2 (en) 1997-09-12 2015-11-18 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
EP1038016A2 (en) 1997-12-16 2000-09-27 Valentis Inc. Needle-free injection of formulated nucleic acid molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
ES2356342T3 (es) 1998-01-05 2011-04-07 The University Of Washington Mejora de transporte utilizando agentes de alteración de membrana.
AR020078A1 (es) 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
ATE237312T1 (de) 1998-07-20 2003-05-15 Protiva Biotherapeutics Inc In liposomen verkapselte nukleinsäurekomplexe
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
BRPI0008131B8 (pt) 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Rna 간섭의 rna 서열 특이적인 매개체
EP1360488B1 (en) 2000-07-26 2016-04-13 ChemoMetec A/S Spatially resolved enzyme-linked assay
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
AUPR894201A0 (en) 2001-11-19 2001-12-13 Women's And Children's Hospital Respiratory delivery for gene therapy and lentiviral delivery particle
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
AU2003261449A1 (en) 2002-08-07 2004-02-25 Compositions for rna interference and methods of use thereof
AU2004221760B2 (en) 2003-03-21 2010-03-18 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
US20050136437A1 (en) 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
WO2005085443A2 (en) * 2004-03-01 2005-09-15 Massachusetts Institute Of Technology Rnai-based therapeutics for allergic rhinitis and asthma
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US7081836B2 (en) 2004-07-09 2006-07-25 The Johns Hopkins University Method and apparatus for covertly detecting and reporting a distress condition in a vehicle control cabin
US7358223B2 (en) 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
WO2006047842A2 (en) 2004-11-08 2006-05-11 K.U. Leuven Research And Development Modified nucleosides for rna interference
SI2727583T1 (sl) 2004-12-22 2022-01-31 Nitto Denko Corporation Nosilec učinkovine in komplet nosilca učinkovine za zaviranje fibroze
WO2007041218A2 (en) * 2005-09-30 2007-04-12 Oklahoma Medical Research Foundation Regulation of tool-like receptors on stem cells
US8362229B2 (en) 2006-02-08 2013-01-29 Quark Pharmaceuticals, Inc. Tandem siRNAS
EP1881080A1 (en) * 2006-07-18 2008-01-23 Institut Gustave Roussy Toll like receptor 4 dysfunction and the biological applications thereof
JP2010507387A (ja) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のsiRNAおよびその使用方法
JP2010527914A (ja) * 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
WO2008154008A1 (en) * 2007-06-11 2008-12-18 The Scripps Research Institute Methods and compositions for inhibiting toll-like receptor mediated immune responses
WO2009015107A1 (en) * 2007-07-20 2009-01-29 Yeda Research And Development Co. Ltd. Modulation of toll-like receptors for controlling neurogenesis
AU2008285626B2 (en) 2007-08-03 2013-09-12 Neuramedy Co., Ltd. Use of TLR-2 antagonists for treatment of reperfusion injury and tissue damage
EP2365814A1 (en) 2008-11-04 2011-09-21 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 4 expression by antisense oligonucleotides
KR20110081336A (ko) 2008-11-04 2011-07-13 이데라 파마슈티칼즈, 인코포레이티드 안티센스 올리고누클레오티드에 의한 toll―유사 수용체 2 발현의 조절
MX2011010616A (es) * 2009-04-09 2012-03-14 Univ North Carolina Metodos para tratar edema relacionado a isquemia-reperfusion.
GB0908425D0 (en) 2009-05-15 2009-06-24 Medical Res Council Medical use
TW201124160A (en) 2009-11-26 2011-07-16 Quark Pharmaceuticals Inc SiRNA compounds comprising terminal substitutions
AU2012223366B2 (en) 2011-03-03 2017-02-23 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
EP2681314B1 (en) 2011-03-03 2017-11-01 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury

Similar Documents

Publication Publication Date Title
JP2014509511A5 (enExample)
JP5996431B2 (ja) 優性変異遺伝子発現抑制剤
ES2556128T3 (es) ARN interfiriente pequeño internamente segmentado
JP2013511990A5 (enExample)
JP2013535212A5 (enExample)
JP2016127853A5 (enExample)
JP2013516190A5 (enExample)
JP2015109851A5 (enExample)
JP2014518612A5 (enExample)
JP2020500929A5 (enExample)
JP2016530882A5 (enExample)
CN110832077B (zh) 用于抑制α-ENaC表达的RNAi剂及使用方法
JP2014527401A5 (enExample)
JP2009514877A5 (enExample)
JP2015523855A5 (enExample)
JP2016513976A5 (enExample)
JP2016116520A5 (enExample)
JP2013514761A5 (enExample)
CN114761557A (zh) 具有最小氟含量的小干扰rna的化学修饰
JPWO2018003739A1 (ja) 機能的リガンドを含む核酸複合体
CN108367021A (zh) 包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
JPWO2017068790A1 (ja) 核酸複合体
WO2012174224A2 (en) Methods for administering nucleic acid-based therapeutics
TW202519663A (zh) 雙股寡核苷酸試劑及其用途
JP2013537404A5 (enExample)